{
}
Pfizer has invested $49 million in Triana Biomedicines to develop molecular glue degraders for oncology, while Tim Buckley joins Pfizer's board amid pressure from activist investors. Jazz Pharmaceuticals reported positive Phase 3 results for Zepzelca in small cell lung cancer, prompting plans for expanded FDA approval. MeiraGTx's gene therapy for Parkinson's disease showed safety and encouraging efficacy in a small trial, and Akeso raised $250 million for international trials of its antibody drugs. Inventiva appointed Mark Pruzanski as chairman, securing $100 million for a Phase 3 trial of lanifibranor.
At the World Health Summit in Berlin, leaders including German Chancellor Olaf Scholz and Health Minister Karl Lauterbach emphasized the need for increased funding for the WHO to combat future pandemics and climate change, pledging hundreds of millions in support. The summit highlighted the importance of global cooperation, with calls for wealthier nations to assist poorer ones in healthcare, and discussions on a proposed global billionaires' tax to enhance financial contributions. The WHO aims to secure over $1 billion for its initiatives, reinforcing its role in international health governance.
Danish drugmaker Lundbeck has agreed to acquire Longboard Pharmaceuticals for $2.6 billion, paying $60 per share, a 54% premium. The deal aims to enhance Lundbeck's portfolio with bexicaserin, a potential treatment for developmental and epileptic encephalopathies, which could generate annual sales of $1.5 billion to $2 billion. The acquisition is expected to close by year-end, positioning Lundbeck for growth as it faces patent expirations on key products.
The FDA has approved Pfizer's Hympavzi for treating hemophilia A and B in patients aged 12 and older without inhibitors. This weekly injection reduces the activity of tissue factor pathway inhibitor, enhancing blood clotting. Hympavzi offers a new treatment option alongside gene therapies and other factor replacement drugs, showing superior results in lowering bleeding rates.
Sanofi is in negotiations with private equity firm Clayton Dubilier & Rice to sell a 50% controlling stake in its consumer health business, Opella, potentially valued at around €15 billion ($16.4 billion). This sale would allow Sanofi to focus more on its biopharmaceutical operations, which generated over €18 billion in sales in the first half of the year. Opella, known for products like Allegra and Icy Hot, operates in 100 countries and employs over 11,000 people.
Two former Pfizer executives, Ian Read and Frank D’Amelio, have distanced themselves from activist investor Starboard Value's plans to overhaul the company, citing support for current management. Starboard alleges they were coerced into this stance, claiming threats of litigation and compensation clawbacks. The investor, which holds a $1 billion stake in Pfizer, is pushing for changes amid the company's declining profitability and challenges in the pharmaceutical market.
A multibillion-dollar race is underway among pharmaceutical companies to develop superior obesity drugs, with key contenders like Eli Lilly's Zepbound and Novo Nordisk's Wegovy leading the market. Upcoming trial results for various drugs, including Amgen's maritide and Roche's CT-996, are highly anticipated and could reshape the competitive landscape. As companies explore innovative approaches, such as preserving muscle mass during weight loss, the future of obesity treatment remains dynamic and closely watched.
David Baker, Demis Hassabis, and John Jumper have won the Nobel Prize in Chemistry for their groundbreaking work in computational protein design and structure prediction, significantly advancing drug design capabilities. Alnylam Pharmaceuticals seeks FDA approval for vutrisiran to treat a severe form of transthyretin amyloidosis, while Johnson & Johnson halts a bladder cancer trial for TAR-200. AstraZeneca invests in a preclinical cholesterol-lowering drug, and Astellas acquires rights to an experimental gene therapy for frontotemporal dementia.
GSK's RSV vaccine, Arexvy, demonstrated 63% overall efficacy and 67% against severe disease over three seasons, though effectiveness declined to 48% in the third season. The CDC currently does not recommend a second dose, but GSK anticipates that revaccination may be necessary to maintain protection. The findings will be presented at the CHEST 2024 Annual Meeting.
Investing in healthcare ETFs offers Canadian investors a way to diversify their portfolios, which are often underweight in this sector. Despite its volatility, the healthcare sector is expected to see growth driven by an aging population, technological advancements, and increased healthcare spending. Funds like the Hamilton Healthcare Yield Maximizer ETF and Harvest Healthcare Leaders Income ETF utilize covered call strategies to enhance yields, appealing to those seeking defensive investments with growth potential.
Pfizer Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
pharmaceutical updates pfizer invests in molecular glue jazz and meiragtx share gains
United States Dollar
MeiraGTx Holdings plc
Jazz Pharmaceuticals plc
Pfizer Inc.
Inventiva S.A.
Hoffmann-La Roche AG
FRA
USA
CHE
CHN
Tim Buckley
Ben Fidler
Jacob Bell
Alexandria Forbes
Mark Pruzanski
Show more
12:47 15.10.2024
global leaders pledge support for who amid pandemic and climate challenges
United States Dollar
Euro
Pfizer Inc.
Microsoft Corporation
BRA
DEU
ZAF
Karl Lauterbach
Bill Gates
Ursula von der Leyen
Svenja Schulze
Olaf Scholz
Show more
09:00 15.10.2024
lundbeck acquires longboard pharmaceuticals for 2.6 billion dollars to enhance brain drug portfolio
United States Dollar
H. Lundbeck A/S
Arena Pharmaceuticals Inc.
Longboard Pharmaceuticals, Inc.
Pfizer Inc.
DNK
Charl van Zyl
Arena Pharmaceuticals
Show more
14:14 14.10.2024
Pfizer's Hympavzi receives FDA approval for hemophilia treatment options
United States Dollar
Pfizer Inc.
CSL Behring
BioMarin Pharmaceutical Inc.
Hoffmann-La Roche AG
Sanofi
USA
Starboard Value
Aamir Malik
Show more
13:45 14.10.2024
sanofi in talks to sell consumer health business to private equity firm
Euro
United States Dollar
Clayton, Dubilier & Rice LLC
McKesson Corporation
Glaxosmithkline Export Ltd.
Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Sanofi
Johnson & Johnson
FRA
USA
François Roger
Merck & Co.
Show more
13:47 11.10.2024
ex pfizer executives allege coercion amid activist investor push for change
United States Dollar
Match Group, Inc.
Pfizer Inc.
Bristol-Myers Squibb Company
News Corporation
USA
Albert Bourla
Ian Read
Frank D'Amelio
Jeffrey Smith
Show more
13:16 10.10.2024
pharmaceutical race intensifies for next generation obesity treatments
United States Dollar
Eli Lilly and Company
Pfizer Inc.
Novo Nordisk A/S
Hoffmann-La Roche AG
Amgen Inc.
USA
DNK
Joe Biden
Donald Trump
David Risinger
Show more
11:49 10.10.2024
nobel prize awarded for protein design and drug developments advance
United States Dollar
Eli Lilly and Company
AviadoBio
Alnylam Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Amgen Inc.
Astellas Pharma Inc.
Pfizer Inc.
BridgeBio Pharma, Inc.
Novartis AG
AstraZeneca PLC
Johnson & Johnson
USA
SWE
JPN
BRA
HKG
John Jumper
David Baker
Jonathan Gardner
Demis Hassabis
Jim Wilson
Show more
13:00 09.10.2024
GSK RSV vaccine shows effectiveness over three seasons but wanes over time
14:15 08.10.2024
healthcare etfs offer growth potential and defensive investment strategies
Eli Lilly and Company
Intuitive Surgical, Inc.
UnitedHealth Group Incorporated
Novo Nordisk A/S
Amgen Inc.
Thermo Fisher Scientific Inc.
Zoetis Inc.
Pfizer Inc.
Merck & Co., Inc.
Agilent Technologies, Inc.
Stryker Corporation
Johnson & Johnson
CAN
USA
Chris Cullen
Novo Nordisk A/S
Mike Clare
Paul MacDonald
Nick Piquard
Show more
09:00 03.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Global Trade Developments
Startups & Entrepreneurship
Stock Market Updates
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Supply Chain Management
Cryptocurrency Trends
Government Economic Policies
Private Equity Deals
Workplace Trends
Central Banks and Digital Currencies
Fintech Startups
CEO Changes
Central Bank Actions
Venture Capital Investments
Retail and Consumer Goods
Finance Mergers & Acquisitions
Global Financial Events
Countries:
Companies:
Apple Inc.
Foxconn Technology Co., Ltd.
NVIDIA Corporation
Nasdaq 100 Jun 25
Tencent Holdings Ltd
Google Inc.
Nikkei 225
Grab2Go AS
Boeing Co
Airbus SE
Amazon.com, Inc.
Oracle AI USD
AppLovin Corp.
Tesmec S.p.A.
DeepSeek R1 USD
LG Electronics Inc.
Tesla, Inc.
MARA Holdings, Inc.
Cleanspark Inc
Citigroup Inc.
Currencies:
United States Dollar
Euro
Indian Rupee
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
New Taiwan Dollar
Indonesian Rupiah
Saudi Riyal
Egyptian Pound
Hong Kong Dollar
Malaysian Ringgit
Filipino Peso
West African CFA Franc
South Korean Won
Thai Baht
Mexican Peso
Croatian Kuna
People: